MDXHealth

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 18 mei 2011 - 08:28

Statutaire naam MDXHealth

Titel MDxHealth Provides First Quarter 2011 Business Update

Bericht DURHAM, NC, and LIEGE, BELGIUM – May 18, 2011 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011. Q1 2011 Highlights • Continued Year-on-Year improvement of key financial performance indicators - Operating loss reduced by 15% - Net loss reduced by 17% - Operating cash flow improved by 21% - Net cash flow improved by 23% • Signed agreement with Pfizer for companion diagnostic tests of an important marker for PARP inhibitor in breast and ovarian cancers • With Merck KGaA, took steps for submission to U.S. FDA of MGMT as a companion diagnostic for its potential inclusion in label of Merck’s brain cancer drug Cilengitide • Licensing partner Predictive BioSciences published promising clinical data on the use of MDxHealth’s technology and markers for bladder cancer detection • Licensing partner Exact Sciences Corp. confirmed use of MDxHealth’s technology/biomarker in their colorectal cancer screening test • Ended the quarter with EUR 9 million cash on hand On April 5, 2011, MDxHealth raised EUR 8.2 million in new funds via a private placement with European institutional investors and thus ended the month of April with EUR 16 million (USD 23 million) of cash on hand. “In the first quarter of 2011, MDxHealth capitalized on the positive momentum we built through 2010,” said Dr. Jan Groen, Chief Executive Officer of MDxHealth. “With our pharmaceutical partners we made continued progress on the development of a number of high-profile companion diagnostic programs and concluded a companion diagnostic agreement with Pfizer for one of their PARP inhibitors that is being developed for breast and ovarian cancers. Finally, our progress resulted in a successful fund raising with investors across Europe, which closed in early April. These funds will be used to execute our strategy to build a commercial laboratory and marketing infrastructure i

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201105180000000009_2011-05-18 MDXH Q1 2011 - FINAL.docx.pdf (opens in a new window)

Datum laatste update: 17 maart 2026